Analysing malaria drug trials on a per-individual or per-clone basis: Acomparison of methods

Statistics in Medicine

Volumn 32, Issue 17, 2013, Pages 3020-3038

  Jaki, Thomas ^a   Parry, Alice ^a   Winter, Katherine ^b   Hastings, Ian ^b  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Clone; Cure rate; Malaria; Per individual; Per clone

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE;

ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE FREQUENCY; GENE LOCUS; GENETIC MARKER; HEALTH STATISTICS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALARIA; MATHEMATICAL MODEL; MEASUREMENT ACCURACY; MIXED INFECTION; MOLECULAR CLONING; OUTCOME ASSESSMENT; PER CLONE BASIS; PER INDIVIDUAL BASIS; RECRUDESCENCE; STATISTICAL ANALYSIS; SURVIVAL;

CLONE; CURE RATE; MALARIA; PER INDIVIDUAL; PER-CLONE;

ANTIMALARIALS; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; GENES, PROTOZOAN; GENETIC MARKERS; HUMANS; MALARIA; MODELS, STATISTICAL; PLASMODIUM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84879998671     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5706     Document Type: Article

References (29)

1. Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malaria Journal 2006; 5(127).
2. Borrmann S, Peto T, Snow RW, Gutteridge W, White NJ. Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. PLoS Medicine 2008; 5(11):1546-1552.
3. Sama W, Owusu-Agyei S, Felger I, Vounatsou P, Smith T. An immigration-death model to estimate the duration of malaria infection when detectability of the parasite is imperfect. Statistics in Medicine 2005; 24(21):3269-3288.
4. Vafa M, Troye-Blomberg M, Anchang J, Garcia A, Migot-Nabias F. Multiplicity of Plasmodium falciparum infection in asymptomatic children in senegal: relation to transmission, age and erythrocyte variants. Malaria Journal 2009; 7(17).
5. World Health Organization. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria, World Health Organization, 2003. Available from: http://whqlibdoc.who.int/hq/2003/WHO_HTM_RBM_2003.50.pdf [accessed on 06/09/2010].
6. Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G. The use of genotyping in antimalaria clinical trials: a systematic review of published studies from 1995-2005. Malaria Journal 2006; 5(122).
7. Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, d'Alessandro U, Guerin PJ, Laufer MK, Naidoo I, Nosten F, Olliaro P, Plowe CV, Ringwald P, Sibley CH, Stepniewska K, White NJ. World antimalarial resistance network I: clinical efficacy of antimalarial drugs. Malaria Journal 2007; 6(119).
8. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJ. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360:2031-2038.
9. Verret W, Dorsey G, Nosten F, Price R. The effect of varying analytical methods on estimates of anti-malarial clinical efficacy. Malaria Journal 2009; 8(77).
10. Guthmann JP, Pinoges L, Checchi F, Cousens S, Balkan S, Van Herp M, Legros D, Olliaro P. Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004. Antimicrobial Agents and Chemotherapy 2006; 50(11):3734-3739.
11. Slater M, Kiggundu M, Dokomajilar C, Kamya MR, Bakyaita N, Talisuna A, Rosenthal PJ, Dorsey G. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. American Journal of Tropical Medicine and Hygiene 2005; 73(2):256-262.
12. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet 2004; 364(9449):1950-1957.
13. Brockman A, Paul RE, Anderson TJ, Hackford I, Phaiphun L, Looareesuwan S, Nosten F, Day KP. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. American Journal of Tropical Medicine and Hygiene 1999; 60(1):14-21.
14. Winter K, Hastings IM. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrobial Agents and Chemotherapy 2011; 55(7):3380-3392.
15. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clinical Trials 2006; 1(1).
16. Greenhouse B, Dokomajilar C, Hubbard A, Rosenthal PJ, Dorsey G. Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrobial Agents and Chemotherapy 2007; 51(9):3096-3103.
17. World Health Organization. Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations, World Health Organization, 2007. Available from: http://whqlibdoc.who.int/publications/2008/9789241596305_eng.pdf [Accessed on 06/09/2010].
18. Hastings IM, Nsanzabana C, Smith TA. A comparison of methods to detect and quantify the markers of antimalarial drug resistance. American Journal of Tropical Medicine and Hygiene 2010; 83(3):489-495.
19. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman and Hall: London, 1993.
20. Arnot DE. The influence of the genetic complexity of Plasmodium falciparum infections on the epidemiology of malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002; 96:131-136.
21. Kyabayinze DJ, Karamagi C, Kiggundu M, Kamya MR, Wabwire-Mangen F, Kironde F, Talisuna A. Multiplicity of Plasmodium falciparum infection predicts antimalarial treatment outcome in Ugandan children. African Health Sciences 2008; 8:200-205.
22. Nsanzabana C. Dynamics of malaria parasite resistance markers in two areas of different transmission intensity. PhD Thesis, University of Neuchatal, Switzerland, 2008.
23. Schoepflin S, Valsangiacomo F, Lin E, Kiniboro B, Mueller I, Felger I. Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malaria Journal 2009; 8:250.
24. Mzilahowa T, McCall PJ, Hastings IM. "Sexual" population structure and genetics of the malaria agent P. falciparum. PLoS One 2007; 2:e613.
25. Porter KA, Burch CL, Poole C, Juliano JJ, Cole SR, Meshnick SR. Uncertain outcomes: adjusting for misclassification in antimalarial efficacy studies. Epidemiology and Infection 2010; 139:544-551.
26. Anderson TJC, Su X, Bockarie M, Lagog M, Day KP. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 1999; 119:113-125.
27. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. TheAmerican Journal of Tropical Medicine and Hygiene 2003; 68:133-139.
28. Mwingira F, Nkwengulila G, Schoepflin S, Sumari D, Beck HP, Snounou G, Felger I, Olliaro P, Mugittu K. Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa. Malaria Journal 2011; 10:79.
29. Koepfli C, Schoepflin S, Bretscher M, Lin E, Kiniboro B, Zimmerman PA, Siba P, Smith TA, Mueller I, Felger I. How much remains undetected? Probability of molecular detection of human plasmodia in the field. PLoS One 2011; 6:e19010.